Table 1.
Binding affinities (1/Ki),a efficacies and cLogD values of new 5-HT4 ligands.
![]() | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Compound | R1 | R2 | R3 | R4 | X | n | 5-HT4Ki (nM)a | h5-HT4Ki (nM)b | Efficacyc | pEC50 | cLogDd |
1 | I | H | OCH2 | OCH2 | O | 2 | 0.20 | 2.2 ± 0.3 | Inv. Ag. | 7.9 | 3.20 |
4 | H | H | OCH2 | OCH2 | O | 2 | 1.4 ± 0.2 | Antagonist | - | 1.74 | |
5 | CN | H | OCH2 | OCH2 | O | 2 | 0.45 | 33 ± 5 | n.m. | n.m. | 2.59 |
6 | H | Me | OCH2 | OCH2 | O | 2 | 9.1 ± 0.7 | Inv.Ag | 8.05 | 2.37 | |
7 | Me | H | OCH2 | OCH2 | O | 2 | 6.3 ± 1 | Antagonist | - | 2.20 | |
8 | Cl | Me | OCH2 | OCH2 | O | 2 | 0.577 | 2.0 ± 0.2 | Inv. Ag. | 7.85 | 3.27 |
9 | Br | Me | OCH2 | OCH2 | O | 2 | 4.5 ± 0.4 | Inv. Ag. | 8.0 | 3.36 | |
10 | I | Me | OCH2 | OCH2 | O | 2 | 7.4 ± 0.5 | Inv. Ag. | 7.7 | 3.41 | |
11 | CN | Me | OCH2 | OCH2 | O | 2 | 37 ± 5 | Inv. Ag. | 7.8 | 2.52 | |
12 | H | H | H | OMe | O | 2 | 50 ± 7 | Ag. | 9.75 | 1.77 | |
13 | H | H | OMe | H | O | 2 | 0.738 | 2.4 ± 0.3 | Antagonist | - | 2.07 |
14 | H | H | OMe | H | N | 2 | 8,664 ± 857 | n.m. | n.m. | 0.16 | |
15 | H | H | OMe | H | O | 1 | 0.901 | 17 ± 1 | n.m. | n.m. | 1.54 |
16 | H | H | OMe | H | O | 3 | 12 ± 1 | n.m. | n.m. | 2.60 | |
17 | F | H | OCH2 | OCH2 | O | 2 | 0.334 | 2.1 ± 0.3 | Inv. Ag. | 8.23 | 2.42 |
18 | H | H | OCH2F | H | O | 2 | 0.334 | 17 ± 1 | n.m. | n.m. | 1.97 |
19 | H | H | O(CH2)2F | H | O | 2 | 0.215 | 11 ± 1 | n.m. | n.m. | 2.30 |
21 | NO2 | H | OCH2 | OCH2 | O | 2 | 7.8 ± 0.9 | n.m. | n.m. | 3.04 |
For guinea pig striatal membrane 5-HT4 receptors. Values are averages of triplicate measurements.
For h5-HT4 receptors. Binding assay results are averages of triplicate measurements.
In agonist/inverse agonist assay. Ag. = agonist; Inv. Ag. = Inverse agonist; n.m. = not measured.
cLogD was calculated with ACD software; estimated errors, are approximately ± 1.0.